Publication | Open Access

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

UrologyGenitourinary CancerStudy 111/Keynote-146MedicinePhase 1B/2Immune Checkpoint InhibitorAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyMolecular Oncology